TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04890197

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tahini
Description: 48 grams tahini

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no intervention
Study: NCT06535945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin administration
Description: when albumin serum concentration is at 30 g/L or below

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin administration
Description: when albumin serum concentration is at 30 g/L or below
Study: NCT05814679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation with virtual reality
Description: In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention match
Description: kidney function instruction
Study: NCT04851145

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mass spectrometry-based proteomics of FFPE biopsies and urine samples
Description: The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~* Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~* Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)
Study: NCT06565494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midomafetamine (MDMA)-Assisted Therapy
Description: This treatment consists 3 Preparation sessions followed by 3 Experimental sessions at 4-week intervals; after each Experimental session, 3 weekly Integration sessions will be conducted. For the first Experimental Session, the dose of MDMA is 80 mg; for the second and third Experimental Sessions, the dose of MDMA is 120 mg. For all three Experimental sessions, a supplemental dose of 50% of the initial dose will be available. The Preparation, Experimental, and Integration Sessions will involve psychotherapy developed specifically for this trial and population.
Study: NCT06188078

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 25 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The bladder stimulation technique
Description: Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 25 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bath
Description: Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies will be bathed under running water 20 minutes after feeding.The bathing process will take 4 minutes in total. After bath, a urine bag will be inserted at the 25th minute of feeding. The success of the transaction and the processing time will be recorded.
Study: NCT06557642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entonox
Description: 30 minute inhalation using demand valve and mouthpiece

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Description: 30 minute inhalation using demand valve and mouthpiece
Study: NCT04862169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention (SPARK)
Description: There are 3 modules with 11 chapters. These topics were considered as the most relevant topics for implementation of palliative care for PHC nurses. Also, topics were selected based on our previous literature review of the previous study on the content of PHC nurses training program.~The first module is the introduction. This consists of three chapters: introduction, support system and effective communication. Total reading time is estimated to be one hour. The second module is about the nursing approach in palliative care. It is estimated to be completed in around 2 hours and 15 minutes. The last module is about end of life care.~The participants are expected to access this module before the scheduled synchronous mode. Modules will be provided in the electronic version, so that participants are able to download and read them on their own devices. We are also providing video as trigger for case study discussion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electronic version of the modules
Description: electronic version of the modules
Study: NCT04542486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of gingival hyperplasia using Soft tissue trimmer .
Description: Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of gingival hyperplasia using the conventional scalpel technique
Description: Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
Study: NCT06640075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community co-produced action
Description: Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive). This intervention is referred to as 'community co-produced action'. Possible strategies co-developed may include collaboration with community health workers or local associations, awareness campaigns, development of health education materials, integration of primary HPV screening at local integrated health centers, organization of group transportation to the district screening center, etc.~Using purposive sampling methods, approximately 15 participants will be invited to take part in the workshops in each health area of the intervention, including approximately 3 health care providers, 3 community health workers or members of women's associations, 3 men and 6 eligible women for screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard screening strategy
Description: Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang. This standard procedure includes the training of 2 community health workers (CHW) by health area to raise awareness around cervical cancer. After an initial theoretical and practical training in cervical cancer prevention, CHWs recruit women by going door-to-door or through community meetings in their respective health areas. Through a system of nominal invitation vouchers distributed to eligible women, CHWs receive a financial incentive for each woman that shows up for cervical cancer screening. Twice a year, CHWs of all health areas are invited to a feedback session to discuss difficulties encountered on the field and propose solutions to face any identified challenges.
Study: NCT05675839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)
Description: Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI_hzY\&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY\&t=284s)
Study: NCT05942573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab+Paclitaxel+Apatinib
Description: Immunotherapy+chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel±Ramucirumab
Description: chemotherapy±Targeted therapy
Study: NCT05382390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Study: NCT04714697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabometyx
Description: Cabometyx 60mg once daily, oral , up to Progression disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabometyx
Description: Cabometyx 60mg once daily, oral , up to Progression disease
Study: NCT05008315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial abdominal diaphragm release
Description: Myofascial abdominal diaphragm release

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial abdominal diaphragm release
Description: Myofascial abdominal diaphragm release

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct focused scar release technique
Description: Direct focused scar release technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct focused scar release technique
Description: Direct focused scar release technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct manipulations to visceral structures
Description: Direct manipulations to visceral structures

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pelvic anatomy education
Description: pelvic anatomy education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic anatomy education
Description: pelvic anatomy education

Intervention type: OTHER
Group type: OTHER
Intervention: pelvic anatomy education
Description: pelvic anatomy education
Study: NCT06482359

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: coformulated CIC Vaccine
Description: SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: coformulated CIC Vaccine
Description: SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: coformulated CIC Vaccine
Description: SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD trivalent
Description: 60 µg per strain of 3 strains (sodium phosphate buffered isotonic sodium chloride solution + formaldehyde and octyl phenol ethoxylate)
Study: NCT05545553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Piezosurgery used as an osteotomy device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional burs
Description: Conventional burs used as an osteotomy device
Study: NCT06321406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES (neuromuscular electrical stimulation)
Description: With this application, swallowing muscles are stimulated and muscle strength increases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Traditional Conservative swallowing treatment
Study: NCT05736718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Champion Announcement Approach Training
Description: AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
Study: NCT06321406

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Traditional Conservative swallowing treatment
Study: NCT05736718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Announcement Approach Training
Description: AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
Study: NCT05442983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™ (probenecid)
Description: Active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™ (probenecid)
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04520854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Protocol
Description: The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
Study: NCT05806359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05533268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental training
Description: Mental training (guided mindfulness meditation by Jon Kabat-Zinn for 20 minutes, 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training (continuous moderate-intensity training at 40-60% of participants' heart rate reserve for 20 minutes excluding warm-up/cool-down, 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental & physical training
Description: Mental and physical training (combination of mindfulness mediation for 20-minutes, 3 times per week and continuous moderate-intensity training for 20 minutes, 3 times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: DASH diet ( (more vegetables, fruits and low-fat dairy foods and moderate amounts of whole grains, fish, poultry and nuts; and less than 3 grams of sodium daily) for 6-weeks.
Study: NCT05450510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated (ACCEL) protocol group
Description: After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow (SLOW) protocol group
Description: After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
Study: NCT05829538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SuJok
Description: Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Description: Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
Study: NCT06304766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ablation
Description: Heat-based ablation modality performed by laparoscopy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open ablation
Description: Heat-based ablation modality performed by laparotomy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
Study: NCT05268679

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
Study: NCT06198491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Misbeliefs about HPV training
Description: Intervention trainings mentioned false beliefs before or after the current knowledge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Misbeliefs about HPV training
Description: Intervention trainings mentioned false beliefs before or after the current knowledge
Study: NCT04747353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation procedure with heart 3D model
Description: Device: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
Study: NCT06106204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROAD Home Intervention
Description: Hospitals randomized to receive the ROAD Home Intervention will undergo (1) a baseline needs assessment to create a customized suite of stewardship strategies, (2) supported decision-making in selecting ROAD Home strategies to implement, and (3) external facilitation following an implementation blueprint.
Study: NCT05360446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg
Description: Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
Study: NCT06099379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
Study: NCT06478979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuclare
Description: It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
Study: NCT05366842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stravix lyopreserved placental tissue (LPT)
Description: Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radical prostatectomy
Description: Standard care (no placement of tissue)
Study: NCT05604547

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-Invasive Infrared Spectroscopy
Description: NIRS is a non-Invasive optical technique for characterizing microvascular hemodynamics.
Study: NCT05967728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) progammable device
Description: RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning (RIC) progammable device
Description: RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.